CL2024001693A1 - Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a. - Google Patents
Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a.Info
- Publication number
- CL2024001693A1 CL2024001693A1 CL2024001693A CL2024001693A CL2024001693A1 CL 2024001693 A1 CL2024001693 A1 CL 2024001693A1 CL 2024001693 A CL2024001693 A CL 2024001693A CL 2024001693 A CL2024001693 A CL 2024001693A CL 2024001693 A1 CL2024001693 A1 CL 2024001693A1
- Authority
- CL
- Chile
- Prior art keywords
- systems
- methods
- treatment
- equipment
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113657P | 2020-11-13 | 2020-11-13 | |
| US202163136153P | 2021-01-11 | 2021-01-11 | |
| US202163147165P | 2021-02-08 | 2021-02-08 | |
| US202163181074P | 2021-04-28 | 2021-04-28 | |
| US202163226032P | 2021-07-27 | 2021-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001693A1 true CL2024001693A1 (es) | 2024-11-29 |
Family
ID=81602611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001693A CL2024001693A1 (es) | 2020-11-13 | 2024-06-07 | Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230272098A1 (https=) |
| EP (1) | EP4244251A4 (https=) |
| JP (1) | JP2023551602A (https=) |
| KR (1) | KR20230140553A (https=) |
| AU (1) | AU2021377688A1 (https=) |
| BR (1) | BR112023009172A2 (https=) |
| CA (1) | CA3197828A1 (https=) |
| CL (1) | CL2024001693A1 (https=) |
| CO (1) | CO2023007607A2 (https=) |
| IL (1) | IL302791A (https=) |
| MX (1) | MX2023005688A (https=) |
| PH (1) | PH12023500011A1 (https=) |
| TW (1) | TW202233685A (https=) |
| WO (1) | WO2022103961A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| TWI845600B (zh) | 2019-01-24 | 2024-06-21 | 美商普羅米修斯生物科學股份有限公司 | Gpr35調節劑 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| WO2022232253A1 (en) * | 2021-04-28 | 2022-11-03 | Cedars-Sinai Medical Center | Patient selection methods and kits for therapies targeting tl1a |
| US20260066079A1 (en) * | 2022-11-23 | 2026-03-05 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| EP4646434A2 (en) * | 2023-01-06 | 2025-11-12 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors |
| EP4646443A1 (en) * | 2023-01-06 | 2025-11-12 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors |
| KR20260013470A (ko) * | 2023-05-17 | 2026-01-28 | 제넨테크, 인크. | 항-tl1a 항체 치료 방법 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0004928D0 (sv) * | 2000-12-29 | 2000-12-29 | Apbiotech Ab | A method for the manufacturing of porous material |
| WO2002059264A2 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General Corp. | Specific human antibodies for selective cancer therapy |
| WO2014186750A2 (en) * | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR102481305B1 (ko) * | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| US10626180B2 (en) * | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| ES2962715T3 (es) * | 2018-04-30 | 2024-03-20 | Cedars Sinai Medical Center | Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias |
| JP2022533956A (ja) * | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
-
2021
- 2021-11-11 CA CA3197828A patent/CA3197828A1/en active Pending
- 2021-11-11 PH PH1/2023/500011A patent/PH12023500011A1/en unknown
- 2021-11-11 JP JP2023553156A patent/JP2023551602A/ja active Pending
- 2021-11-11 WO PCT/US2021/058979 patent/WO2022103961A1/en not_active Ceased
- 2021-11-11 KR KR1020237019762A patent/KR20230140553A/ko active Pending
- 2021-11-11 BR BR112023009172A patent/BR112023009172A2/pt unknown
- 2021-11-11 EP EP21892810.9A patent/EP4244251A4/en active Pending
- 2021-11-11 AU AU2021377688A patent/AU2021377688A1/en active Pending
- 2021-11-11 IL IL302791A patent/IL302791A/en unknown
- 2021-11-11 MX MX2023005688A patent/MX2023005688A/es unknown
- 2021-11-12 TW TW110142315A patent/TW202233685A/zh unknown
-
2023
- 2023-05-12 US US18/316,811 patent/US20230272098A1/en active Pending
- 2023-06-08 CO CONC2023/0007607A patent/CO2023007607A2/es unknown
-
2024
- 2024-06-07 CL CL2024001693A patent/CL2024001693A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230272098A1 (en) | 2023-08-31 |
| KR20230140553A (ko) | 2023-10-06 |
| EP4244251A4 (en) | 2025-04-16 |
| AU2021377688A1 (en) | 2023-06-29 |
| AU2021377688A9 (en) | 2024-09-12 |
| JP2023551602A (ja) | 2023-12-08 |
| BR112023009172A2 (pt) | 2023-10-03 |
| PH12023500011A1 (en) | 2024-03-11 |
| WO2022103961A1 (en) | 2022-05-19 |
| EP4244251A1 (en) | 2023-09-20 |
| TW202233685A (zh) | 2022-09-01 |
| CA3197828A1 (en) | 2022-05-19 |
| IL302791A (en) | 2023-07-01 |
| MX2023005688A (es) | 2023-07-18 |
| CO2023007607A2 (es) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001693A1 (es) | Métodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a. | |
| MX2025005963A (es) | Métodos, sistemas y kits para el tratamiento de enfermedades inflamatorias dirigidos a tl1a | |
| CL2021000153A1 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| JOP20190272A1 (ar) | مثبطات kras g12c وطرق لاستخدامها | |
| MX2021014302A (es) | Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa. | |
| CY1124476T1 (el) | Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| EA202191557A1 (ru) | Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк | |
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| AU2019310335A8 (en) | Methods of treating cancer with PI3K inhibitor, GDC-0077 | |
| CL2021002878A1 (es) | Tratamiento y prevención de enfermedades metabólicas | |
| MX2024012024A (es) | Combinaciones para usarse en el tratamiento o la prevencion del cancer | |
| EA201391208A1 (ru) | КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ mTOR/JAK | |
| AR061230A1 (es) | Prolongacion de la supervivencia de pacientes con cancer con niveles elevados de egf o tgf-alfa | |
| EA201500334A1 (ru) | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него | |
| MX2018004286A (es) | Metodos de tratamiento de lesiones o condiciones relacionadas con el edema del sistema nervioso central. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112021020525A2 (pt) | Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação | |
| ZA202103975B (en) | Methods of treating disease with magl inhibitors | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| MX386249B (es) | Terapia tusc2 para usarse en el tratamiento de cáncer. | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| MX2021009182A (es) | Antiandrogenos para el tratamiento de cancer de prostata metastasico sensible a la castracion. | |
| MX2021014015A (es) | Metodos basados en el genoma para reducir el riesgo cardiovascular. | |
| MX2025014136A (es) | Metodos, sistemas y kits para el tratamiento de enfermedades inflamatorias mediante el direccionamiento a tl1a |